Refine by
Healthcare Quality Management Articles & Analysis
71 news found
Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program, a co-sell program for AWS partners that provide software solutions that run on or integrate with AWS. ...
("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today released a statement regarding the mass shooting incident that took place in Monterey Park, Calif., the evening of January 21, ...
We truly believe that our continued ability to deliver leading results in healthcare delivery for Original Medicare patients across the country is validation of ApolloMed's physician-centric, tech-enabled, value-based care model. This is, at its core, a superior level of care coordination and population health management that allows our providers to deliver ...
Manage your healthcare with the use of HEDIS (Healthcare Effectiveness Data and Information Set) and OMW (Osteoporosis Management in Women). ...
Morgan Healthcare Conference on Wednesday, January 11, 2023, at 1:30 p.m. PT/4:30 p.m. ...
BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced that, together with Finland’s Euformatics and Hungary’s Oncompass Medicine, the BCP-led partnership has now successfully been awarded contract for the second phase of developing standardized oncology workflows for a buyer consortium of seven leading ...
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of pediatric endocrinology for a discussion of interim data from our Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD). The KOL webinar will ...
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the Piper Sandler 34th Annual Healthcare Conference November 29th through December 1st. Event: Piper Sandler 34th Annual ...
To add to the confusion and clutter, outside of asset management, the term digital twin is used widely as technology companies work to revolutionise everything from healthcare and facilities management, to manufacturing, construction, defence and science. ...
("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that ApolloMed received certification from the National Committee for Quality Assurance ("NCQA") ...
Through this transaction, ApolloMed will deploy its value-based care management and operational platform to empower VOMG's employed providers to deliver best-in-class clinical outcomes while improving the healthcare experience for its patients. ...
Why should payers care about clinical laboratory testing? Clinical laboratory testing plays an essential role in the delivery of health care. From early detection and diagnosis of disease to individualized treatment plans based on a person’s unique biology, medical care depends on accurate and timely health data. Seventy percent of medical decisions depend on lab test results, so making ...
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October. Event: Cantor Neurology ...
("FYB"), as well as certain related managed care assets. AAMG is a primary and specialty care physicians' group focused on providing high-quality, culturally competent care to local communities in the San Francisco Bay Area. ...
During the event, the United States and Saudi Arabia signed 18 partnership agreements in industries such as energy, space and healthcare. Aerospace companies Boeing and Raytheon, as well as healthcare companies such as Medtronic and IQVIA were among the partnerships announced. ...
Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, today announced that Fran Soistman has joined the company’s Scientific Advisory Board (SAB). Soistman is an accomplished business executive who has decades of experience driving profitable growth for healthcare entities. As a member of ...
Saladax Biomedical, Inc. (Saladax) is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio includes 17 patent families and has resulted in 33 U.S. patents and 296 patents in ex-U.S. countries. This IP, along with the current Saladax IP, covers the major antipsychotic drugs that are ...
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that John McKew, PhD, President and Chief Scientific Officer of Lumos Pharma, will participate in a panel discussion at the Cantor Rare Disease Symposium at the end of March 2022. Event: Cantor Rare Disease Symposium – March 28-30 Presentation: Panel ...
The end-result is a high-quality, 3D model of the shoulder bones, which allows exceptional planning for TSA, without the need for a CT scan for planning. ...
A July 2019 White House executive order on kidney care (the Advancing American Kidney Health Initiative) proposed that 80% of new patients with end-stage renal disease (ESRD) be treated with either kidney transplantation or home dialysis by 2025, a significant increase from current rates, which are below 20%. “End-stage renal disease, one of the costliest chronic diseases in the U.S., is ...